CDK

Cyclin-dependent kinases (CDKs) are the families of protein kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells.They are present in all known eukaryotes, and their regulatory function in the cell cycle has been evolutionarily conserved.

Cat No.	product name
T10096	(2S,3R)-Voruciclib	(2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. It is an orally active CDK inhibitor.
T10220	Abemaciclib Metabolites M2	Abemaciclib Metabolites M2 is a metabolite of abemaciclib, acts as a potent CDK4 and CDK6 inhibitor (IC50s: 1-3 nM) with anti-cancer activity.
T10382	AS2863619 free base	AS2863619 free base enables the conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells. It is a potent, orally active CDK8...
T10436	AZD4573	AZD4573 is an effective and selective CDK9 inhibitor (IC50: <4 nM). It enables transient target engagement for the treatment of hematologic malignancies.
T10464	Atuveciclib	Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb/CDK9 inhibitor. It inhibits CDK9/CycT1 (IC50: 13 nM).
T10464L	Atuveciclib Racemate	Atuveciclib is a potent and highly selective, oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM. Atuveciclib Racemate (BAY-1143572 Rac...
T10465	Atuveciclib S-Enantiomer	Atuveciclib (BAY-1143572) S-enantiomer is a potent and selective CDK9 inhibitor (IC50: 16 nM for CDK9/CycT1).
T10546	bio-THZ1	bio-THZ1 is a biotinylated version of THZ1. THZ1 is a selective and irreversibly covalent CDK7 inhibitor (IC50: 3.2 nM).
T10550	Bisindolylmaleimide X hydrochloride	Bisindolylmaleimide X hydrochloride (BIM-X hydrochloride) is a potent and selective PKC inhibitor. It is also a potent CDK2 antagonist (IC50: 200 nM).
T10724	Cdc7-IN-1	Cdc7-IN-1 is a highly selective and ATP competitive inhibitor of Cdc7 kinase (IC50: 0.6 nM at 1 mM ATP). It potently inhibits Cdc7 activity in cancer cells and ...
T10735	CDK4/6/1 Inhibitor	CDK4/6/1 Inhibitor is a CDK4/6 inhibitor (IC50s: 3 and 1 nM).
T10736	CDK4/6-IN-2	CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor (IC50s: 2.7 and 16 nM) extracted from patent US20180000819A1 (Compound 1).
T10737	CDK4/6-IN-3	CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.
T10738	CDK4/6-IN-4	CDK4/6-IN-4 is a selective CDK4/6 inhibitor and the active metabolite of Abemaciclib.
T10739	CDK8/19-IN-1	CDK8/19-IN-1 is a selective and oral bioavailable CDK8/19 dual inhibitor (IC50s: 0.46 nM, 0.99 nM, and 270 nM for CDK8, CDK19, and CDK9).
T10740	CDK8-IN-1	CDK8-IN-1 is a selective CDK8 inhibitor (IC50: 3 nM).
T10741	CDK9-IN-1	CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection (IC50: 39 nM for CDK9/CycT1).
T10742	CDK9-IN-10	CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.
T10743	CDK9-IN-11	CDK9-IN-11 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-1.
T10744	SEL120-34A	SEL120-34A is a selective, orally available, and ATP-competitive CDK8 inhibitor (IC50s: 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC) with antitumor activity...
T10744L	SEL120-34A HCl	SEL120-34A HCl is a selective, orally available and ATP-competitive inhibitor of CDK8(CDK8/CycC and CDK19/CycC with IC50s of 4.4 nM and 10.4 nM , respectively),...
T10744L2	SEL120-34A monohydrochloride	SEL120-34A monohydrochloride is an ATP-competitive and selective inhibitor of CDK8(CDK8/CycC and CDK19/CycC complexes with IC50s of 4.4 nM and 10.4 nM, respecti...
T10745	CDK9-IN-7	CDK9-IN-7 is a highly selective and orally active CDK9/cyclin T inhibitor (IC50: 11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD: 148 nM; CDK6/...
T10746	CDK9-IN-8	CDK9-IN-8 is a highly potent and selective CDK9 inhibitor (IC50: 12 nM).
T10747	CDK9-IN-9	CDK9-IN-9 is a potent and selective CDK9 inhibitor (IC50: 1.8 nM) with anti-cancer activity. It inhibits CDK2 (IC50: 155 nM).
T10836	CLK1-IN-1	CLK1-IN-1 is a potent and selective inhibitor of the Cdc2-like kinase 1 (CLK1; IC50: 2 nM).
T10898	Samuraciclib hydrochloride	Samuraciclib hydrochloride (CT7001 hydrochloride; ICEC0942 hydrochloride) is a potent, selective, ATP competitive and oral active CDK7 inhibitor with IC50 of 41...
T11309	FMF-04-159-2	FMF-04-159-2 inhibits CDK14 and CDK2 with IC50s of 39.6 nM and 256 nM in NanoBRET assay, respectively. FMF-04-159-2 is a covalent CDK14 inhibitor.
T11345	Lerociclib	Lerociclib (G1T38) is a potent and selective inhibitor of CDK4/6, with IC50s of 2nM, 1 nM for CDK6/CyclinD3 and CDK4/CyclinD1, respectively.
T11345L	Lerociclib dihydrochloride	Lerociclib dihydrochloride is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 2 nM and 1 nM for CDK6/CyclinD3 and CDK4/CyclinD1, respectively.
T11632	IIIM-290	IIIM-290 is an oral CDK inhibitor (IC50s: 90 and 94 nM for CDK2/A and CDK9/T1).
T11655	Indomethacin-D4	Indomethacin-D4 is a deuterium labeled Indomethacin. Indomethacin is a potent and nonselective inhibitor of COX1 and COX2, with IC50s of 18 nM and 26 nM for hum...
T11656	Indoramin D5	Indoramin D5 is a piperidine antiadrenergic agent. Indoramin D5 is deuterium labeled Indoramin.
T11723	JNJ-39758979 dihydrochloride	JNJ-39758979 dihydrochloride functionally antagonizes histamine-induced cAMP inhibition with a pA2 of 7.9 in transfected cells. JNJ-39758979 dihydrochloride sho...
T12355	Palbociclib D8	Palbociclib D8 is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active inhibitor of CDK4 and CDK6 (IC50s of 11 and 16 nM, respectively)...
T12552	PROTAC CDK2/9 Degrader-1	PROTAC CDK2/9 Degrader-1 is a potent CDK2 and CDK9 dual degrader(DC50 of 62 nM and 33 nM).
T12617	(R)-CR8 trihydrochloride	(R)-CR8 trihydrochloride is a potent inhibitor CDK1/2/5/7/9.
T12617L	(R)-CR8	(R)-CR8 is a potent and selective CDK inhibitor.
T12642L	Simurosertib	Simurosertib is a selective and ATP-competitive cell division cycle 7 kinase inhibitor (IC50: <0.3 nM).
T13044	SY-1365	SY-1365 is a highly selective covalent CDK7 inhibitor. SY-1365 possesses therapeutic potential in both hematological and solid tumors.